CDR132L Clinical Trials (2026): 5 Studies for Heart Failure & Heart Failure With Preserved Ejection Fraction
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 CDR132L clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Heart Failure & Heart Failure With Preserved Ejection Fraction) and 722 total planned enrollment. 2 CDR132L clinical trials are actively recruiting at 9 U.S. sites across 6 states. Most recent activity: NCT06979375 (Jan 2028).
Where to Participate: All CDR132L Trial Sites in the U.S. (9 sites across 6 states)
Every actively recruiting CDR132Ltrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Univ of Alabama Birmingham | Birmingham35233 | NCT06979362 | Map |
| CA | Valley Clinical Trials | Covina91723 | NCT06979362 | Map |
| CA | Valley Clinical Trials | Northridge91325 | NCT06979362 | Map |
| CA | University of California San Francisco UCSF | San Francisco94143 | NCT06979362 | Map |
| FL | Inpatient Research Clinic LLC | Miami Lakes33014 | NCT06979362 | Map |
| MI | Henry Ford Hospital_Detroit | Detroit48202 | NCT06979362 | Map |
| PA | Capital Area Research LLC | Camp Hill17011 | NCT06979362 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390-9302 | NCT06979362 | Map |
| TX | East Texas Cardiology PA | Houston77002 | NCT06979362 | Map |
CDR132L clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | withdrawn | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | ||
| P2 | 2 | 1 | 1 | 4 |
Recruiting CDR132L clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06979375 | 8282-ReducedA Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy | P2 | Heart Failure | 200 | Jun 2025 |
| NCT06979362 | 8212-PreservedA Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy | P2 | Heart Failure | 200 | Jun 2025 |
CDR132L clinical trials by indication
Heart Failure (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06979375 | 8282-Reduced | P2 | recruiting | A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy |
| NCT06979362 | 8212-Preserved | P2 | recruiting | A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy |
| NCT04045405 | — | P1 | completed | Clinical Study to Assess Safety, PK and PD Parameters of CDR132L |
Heart Failure With Preserved Ejection Fraction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05953831 | REMOD-REVERT | P2 | withdrawn | Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy |
Myocardial Infarction, Acute (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05350969 | HF-REVERT | P2 | completed | Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction |
CDR132L pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| 8282-Reduced | NCT06979375 | P2 | recruiting | Heart Failure | 200 | — |
| 8212-Preserved | NCT06979362 | P2 | recruiting | Heart Failure | 200 | — |
| REMOD-REVERT | NCT05953831 | P2 | withdrawn | Heart Failure With Preserved Ejection Fraction | 0 | — |
| HF-REVERT | NCT05350969 | P2 | completed | Myocardial Infarction, Acute | 294 | PMID 42108271 |
Terminated and withdrawn CDR132L trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05953831withdrawnReverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
All CDR132L trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06979375 | 8282-Reduced | A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy | P2 | recruiting | 200 | Novo Nordisk A/S | Jun 2025 |
| NCT06979362 | 8212-Preserved | A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy | P2 | recruiting | 200 | Novo Nordisk A/S | Jun 2025 |
| NCT05953831 | REMOD-REVERT | Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy | P2 | withdrawn | 0 | Cardior Pharmaceuticals GmbH | Apr 2024 |
| NCT05350969 | HF-REVERT | Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction | P2 | completed | 294 | Cardior Pharmaceuticals GmbH | Jul 2022 |
| NCT04045405 | Clinical Study to Assess Safety, PK and PD Parameters of CDR132L | P1 | completed | 28 | Cardior Pharmaceuticals GmbH | Jun 2019 |
CDR132L clinical trials: frequently asked questions
- How many CDR132L clinical trials are there?
- 5 CDR132L clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 2 are marked completed.
- Are CDR132L clinical trials recruiting in 2026?
- Yes — 2 CDR132L trials are actively recruiting in 2026, with 9 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is CDR132L being studied for?
- CDR132L is being studied for Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure, Left Sided, Myocardial Infarction, Acute. The trials are grouped by indication on this page.
- What phase is CDR132L in?
- CDR132L clinical trials span 4 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors CDR132L clinical trials?
- The lead sponsor across the most CDR132L trials is Cardior Pharmaceuticals GmbH, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming CDR132Las an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: